Search
Ambenonium
go.drugbank.com/drugs/DB01122ApprovedWithdrawnAmbenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis.
Vemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigational[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF. … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.
Cobicistat
go.drugbank.com/drugs/DB09065ApprovedInvestigationalMore specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1
Thiocolchicoside
go.drugbank.com/drugs/DB11582InvestigationalIt has potent convulsant activity and should not be administered to individuals prone to seizures.[L1663]
Products: TIOCOLCHICOSIDE DOC GENERICI, TIOCOLCHICOSIDE MYLAN GENERICSLasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnLasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity.
Fludrocortisone
go.drugbank.com/drugs/DB00687ApprovedInvestigationalof the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. … [A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position
Zileuton
go.drugbank.com/drugs/DB00744ApprovedWithdrawnThese effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients.
Categories: Agents to Treat Airway DiseaseBlinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigationalSince blinatumomab has an affinity to both antigens, it redirects T-cells to tumor cells expressing CD19 and promotes tumor cell lysis and apoptosis. … [L46991,L46996] Blinatumomab has a short half-life, requiring patients to receive a continuous infusion over 4-week cycles using a portable mini-pump for optimum delivery.[A254826]